Alan J Franklin, MD, PhD earned a PhD at Vanderbilt University in the Department of Molecular Physiology and Biophysics. He did his residency at Saint Louis University, where he was chief resident, and completed his training at the University of Iowa Hospitals and Clinics for vitreoretinal diseases and surgery, where he secured both HEED and HEED-Knapp scholarships. His research work on an anti-vascular agent as a candidate to diabetic retinopathy and age-related macular degeneration was awarded the best research project at the AUPO meeting. Dr. Franklin has continued his interest in pathological ocular neovascularization as a founding member and chief medical officer of RFE Pharma. He has served on advisory boards for major ophthalmic pharmaceutical companies such as Novartis, Alcon, Eyetech, Pfizer, and QLT.